Neuro Imaging and Multimodal Alzheimer's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

59 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-06-30

Study Completion Date

2012-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present study aimed at measuring cerebral changes in Alzheimer Disease (AD) patients, who responded to strict physiological criteria typical of AD pathology. The objective of the present study was to identify the earliest alterations in cerebral connections that could contribute to the initial episodic memory impairment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Alteration by Magnetic Resonance Imaging (MRI) in Dementia Among Elderly Subjects

NCT00951197

Dementia Alzheimer Disease

COMPLETED

Multi-modal Neuroimaging in Alzheimer's Disease

NCT01638949

Alzheimer's Disease

COMPLETED NA

Multi-modal Neuroimaging in Alzheimer's Disease

NCT01554202

Alzheimer's Disease

UNKNOWN NA

FluoroAv45 Imaging Research-in Alzheimer's Disease

NCT01325259

Alzheimer's Disease Mild Cognitive Impairment

COMPLETED PHASE2

Cognitive Function and Prevalence of Amyloid Marker in Frail Older Adults

NCT03129269

Frail Elderly

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with Alzheimer Disease

Patients will have Neuroimaging by Florbetapir (AV-45)-positron emission tomography

Group Type EXPERIMENTAL

Neuroimaging

Intervention Type RADIATION

AV45-positron emission tomography

Controls patients

Controls will have neuroimaging by AV45-positron emission tomography

Group Type ACTIVE_COMPARATOR

Neuroimaging

Intervention Type RADIATION

AV45-positron emission tomography

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Neuroimaging

AV45-positron emission tomography

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

For all subjects :

* Capacities visual, auditory (authorized devices) and oral or written expression sufficient for the proper performance of tests
* Obtain informed written consent of the subject

Patients with AD :

* Outpatient accompanied by a "helping"
* No parenchymal lesions allowing isolation explain the symptoms on brain MRI (T1 and T2) carried more than 6 months prior to enrollment in the study. Patients with more than three hyperintense white matter or visible lacunar infarction or T2 FLAIR will not be included in the study.
* probable Alzheimer's disease diagnosis par with international standards
* Illness in a mild stage (CDR 1, 24 ≥ Mini-Mental State Examination (MMSE)\> 18)
* activity of daily living (ADL) 4 items\> 1/4

Patients with Alzheimer's disease at a pre-dementia stage:

* Alzheimer's Diagnosis pre-dementia based on the search criteria
* Illness in a mild stage (CDR 0.5, 30 ≥ MMSE ≥ 25)
* ADL items ≤ 4 1/4

Control subjects :

* 30 ≥ MMSE ≥ 27
* perfect autonomy in daily living (IADL = 0, CDR = 0)
* Neuropsychological evaluation not highlighting of impaired cognitive performance with focus on memory performance
* No parenchymal lesions on brain MRI.
* Lack of family history (first degree) of Alzheimer's disease

Exclusion Criteria

* Subjects with a contra-indication to MRI (carrying a pacemaker or cardiac defibrillator, implanted a material activated by an electrical, magnetic or mechanical carriers hemostatic clips intracerebral aneurysms or carotid artery , holders of orthopedic implants, claustrophobia)
* Subjects with clinically significant gastrointestinal, renal, hepatic, endocrine, or cardiovascular
* Subjects with a psychiatric disorder or progressive neurological
* French Language level insufficient to be appropriately involved in neurophysiological evaluation
* less than 5 years Education (insufficient understanding level to participate in the study)
* Administrative problems: unable to give informed about information, not covered by a social security system
* Hypersensitivity to the active substance or to any of the excipients
* unbalanced diabetes mellitus
* Subjects treated by a non-steroidal anti-inflammatory

Minimum Eligible Age

60 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No